Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Is a
Allocation Type
Randomized
0
Health Conditions in Trial
Intervention Model
Parallel Assignment
0
Interventional Trial Phase
Phase 3
0
Interventional Trial Purpose
Treatment
0
Last Updated
May 5, 2020
0
Masking Type
Double
0
Primary Completion Date
May 1, 2006
0
Trial Recruitment Size
86
0
Trial Sponsor
Clinical Trial Start Date
March 23, 2004
0
Study Completion Date
May 1, 2006
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES
0
Official Website
Find more entities like Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.